2016
DOI: 10.1097/dcr.0000000000000594
|View full text |Cite
|
Sign up to set email alerts
|

Systematic Review of Surgical Treatments for Fecal Incontinence

Abstract: Evidence was insufficient to support clinical or policy decisions for any surgical treatments for fecal incontinence in adults. More invasive surgical procedures had substantial complications. The lack of compliance with study reporting standards is a modifiable impediment in the field. Future studies should focus on longer-term outcomes and attempt to identify subgroups of adults who might benefit from specific procedures.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
31
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(32 citation statements)
references
References 104 publications
0
31
0
1
Order By: Relevance
“…Furthermore, muscle‐derived stem cells or progenitor cells differentiate into heterogeneous cells regardless of the sphincter muscle type required by the FI patient . With our strategy, smooth muscle progenitor cells can be used to treat the IAS, and skeletal muscle progenitor cells can be used to treat the EAS; thus, the specific muscle involved in the individual FI patient can be targeted according to the aetiology .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, muscle‐derived stem cells or progenitor cells differentiate into heterogeneous cells regardless of the sphincter muscle type required by the FI patient . With our strategy, smooth muscle progenitor cells can be used to treat the IAS, and skeletal muscle progenitor cells can be used to treat the EAS; thus, the specific muscle involved in the individual FI patient can be targeted according to the aetiology .…”
Section: Discussionmentioning
confidence: 99%
“…progenitor cells differentiate into heterogeneous cells regardless of the sphincter muscle type required by the FI patient [23]. With our strategy, smooth muscle progenitor cells can be used to treat the IAS, and skeletal muscle progenitor cells can be used to treat the EAS; thus, the specific muscle involved in the individual FI patient can be targeted according to the aetiology [24]. This study showed that multiple markers, including CD34, NG2, PAX7, desmin, calponin, a-SMA, MYOG and MyHC, define a cellular hierarchy and allow the selection of specific subpopulations of cells.…”
Section: Discussionmentioning
confidence: 99%
“…For the purpose of curing FI, main therapies are anal sphincter repair , reconstruction of anal sphincter , colostomy , and sacral nerve stimulation . However, none of these therapies is suitable for all FI situations.…”
Section: Introductionmentioning
confidence: 99%
“…However, none of these therapies is suitable for all FI situations. Meanwhile, the rate of complication after these therapies can reach to 21%~71% [7][8][9][10][11] . As the result of that, AAS is launched to create another therapy for FI.…”
Section: Introductionmentioning
confidence: 99%
“…Faecal incontinence is a problem that affects between 1.4% and 19.5% of the population . There is consensus that, when medical treatment and/or biofeedback fails, surgery is the only option . Surgical procedures include sphincteroplasty, bulking agents, sacral nerve stimulation – or a colostomy when everything else fails .…”
mentioning
confidence: 99%